Agios Pharmaceuticals logo

Agios Pharmaceuticals

AGIO | NASDAQ
Chart Builder DCF Calculator
$30.15
-$1.44 (-4.56%)
At close: Nov 16, 2026, 4:00 PM ET
$29.55
-$0.60 (-1.99%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.56%

Rating

Updated: Nov 16, 2026
42.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #455/1021 (Top 45%)

Key Statistics

Market Data

Market Cap $1.8B
1D Range
30.10 31.70
52W Range
22.34 45.49

Valuation (TTM)

PE -4.77
PB 1.84
EV/EBITDA -3.17

Valuation (NTM)

Forward PE N/A
Forward PEG 0.24
Price Target $35.00
Loading financial charts...

Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The compa...

Sector Healthcare
Industry Biotechnology
Employees 540
IPO Date Jul 24, 2013
Fiscal Year January - December

Latest News

Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript

10 days ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

12 days ago · zacks.com

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

12 days ago · globenewswire.com

Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)

18 days ago · seekingalpha.com

Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

18 days ago · globenewswire.com

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

19 days ago · zacks.com

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

1 month ago · globenewswire.com

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

1 month ago · zacks.com

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

2 months ago · zacks.com

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$1.09
Beat +12.10%
REV
$55.39M
Beat +7.24%
Next Earnings
Feb 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$35.00
Upside
+16.09%
Buy (5)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.